VALENCIA, 11 Jan. (EUROPA PRESS) –
The Food Technology Institute (Ainia) investigates innovative therapies to combat the bacteria that cause cavities within the framework of the Healthytooth II project, supported by Ivace and with Feder funds. Specifically, it works on therapies based on phages and endolysins with which to obtain an active ingredient to combat the microorganisms that cause this damage produced on the surface of the tooth, as reported by the entity in a statement.
Caries occupies the first position with respect to other common diseases, with 35 million people affected in Spain. By age groups, the prevalence in young adults (35-44 years) stands out, reaching 94 percent, that is, more than 17 million people affected by dental caries. In older adults (65-74 years) it affects 6.4 million people, according to a report prepared by the General Council of Dentists of Spain.
Dental caries is the most widespread chronic disease in the world and constitutes a “major challenge” for public health. Currently, there are no specific solutions that effectively combat the microorganisms responsible for cavities, despite it being the most common dental disorder. Recommendations to prevent this condition focus on a sugar-free diet, the use of fluoride products to strengthen tooth enamel, and early detection through regular visits to the dentist.
For this reason, Ainia is working on the development of new therapeutic strategies for the prevention and treatment of dental caries. According to the institute, the appearance of cavities is related to the presence of certain microorganisms, such as Streptococcus mutans, Lactobacillus sp. and Actinomyces sp., which tend to form biofilms in dental plaque, as well as in saliva, which promote their appearance.
Ainia is researching the development of bioactive ingredients (enzybiotic compounds) obtained from bacteriophage viruses with specific antimicrobial effect, to effectively combat caries. The ability of endolysins to eliminate antibiotic-resistant pathogenic bacteria present in the mucous membranes and tissues of infected organisms has been demonstrated, respecting the microbiota of the oral mucosa.
The Healthytooth II project aims to continue with the research of the first phase, aimed at obtaining an active ingredient capable of combating the microorganisms that cause cavities.
